Stock Analysis on Net
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Balance Sheet: Liabilities and Stockholders’ Equity

Celgene Corp., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Short-term borrowings and current portion of long-term debt 501 — 501 — 606
Accounts payable 418 305 247 241 198
Rebates, distributor chargebacks and distributor services 1,107 814 561 367 233
Compensation 391 358 414 353 318
Clinical trial costs and grants 475 622 342 255 190
Litigation-related loss contingency — — 199 — —
Interest 238 173 168 170 59
Sales, use, value added, and other taxes 66 59 101 69 66
Milestones payable — 62 — — —
Success payment liability 70 — — — —
Short-term contingent consideration and success payments 60 — 47 109 35
Royalties, license fees and collaboration agreements 114 52 — — —
Deferred tax liability — — — — 131
Other 466 383 285 324 236
Accrued expenses and other current liabilities 2,987 2,523 2,115 1,648 1,267
Income taxes payable 78 84 41 20 13
Current portion of deferred revenue 73 75 55 61 29
Current liabilities 4,057 2,987 2,959 1,969 2,112
Deferred revenue, net of current portion 73 34 28 30 28
Income taxes payable 2,190 2,490 420 324 273
Deferred income tax liabilities 2,753 1,327 — 378 556
Other non-current tax liabilities — — 2,519 2,519 —
Contingent consideration 103 80 1,443 1,412 1,245
Deferred compensation and long-term incentives 243 240 215 171 151
Contingent value rights 19 42 45 52 136
Derivative contracts 21 134 1 — —
Other 91 48 68 30 50
Other non-current liabilities 477 544 1,771 1,664 1,581
Long-term debt, net of discount, excluding current portion 19,769 15,838 13,789 14,250 6,266
Non-current liabilities 25,262 20,233 18,527 19,166 8,703
Total liabilities 29,319 23,220 21,486 21,134 10,815
Preferred stock, $.01 par value per share; none outstanding — — — — —
Common stock, $.01 par value per share 10 10 10 9 9
Common stock in treasury, at cost (26,336) (20,243) (16,281) (14,052) (10,699)
Additional paid-in capital 14,978 13,806 12,378 11,119 9,827
Retained earnings 17,559 13,061 10,074 8,074 6,472
Accumulated other comprehensive income (loss) (50) 287 419 768 915
Stockholders’ equity 6,161 6,921 6,599 5,919 6,525
Total liabilities and stockholders’ equity 35,480 30,141 28,086 27,053 17,340

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).